Journal ArticleDOI
Postoperative Radiotherapy in High-Risk Premenopausal Women with Breast Cancer Who Receive Adjuvant Chemotherapy
Marie Overgaard,Per S. Hansen,Jens Overgaard,Carsten Rose,Martin Andersson,Flemming W. Bach,Mogens Kjaer,Carl C. Gadeberg,Henning T. Mouridsen,Maj-Britt Jensen,Karin Zedeler +10 more
TLDR
Multivariate analysis demonstrated that irradiation after mastectomy significantly improved disease-free survival and overall survival, irrespective of tumor size, the number of positive nodes, or the histopathological grade.Abstract:
Background Irradiation after mastectomy can reduce locoregional recurrences in women with breast cancer, but whether it prolongs survival remains controversial. We conducted a randomized trial of radiotherapy after mastectomy in high-risk premenopausal women, all of whom also received adjuvant systemic chemotherapy with cyclophosphamide, methotrexate, and fluorouracil (CMF). Methods A total of 1708 women who had undergone mastectomy for pathological stage II or III breast cancer were randomly assigned to receive eight cycles of CMF plus irradiation of the chest wall and regional lymph nodes (852 women) or nine cycles of CMF alone (856 women). The median length of follow-up was 114 months. The end points were locoregional recurrence, distant metastases, disease-free survival, and overall survival. Results The frequency of locoregional recurrence alone or with distant metastases was 9 percent among the women who received radiotherapy plus CMF and 32 percent among those who received CMF alone (P<0.001). The ...read more
Citations
More filters
Journal ArticleDOI
Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials.
Mike Clarke,Rory Collins,Sarah C. Darby,C Davies,P. Elphinstone,V Evans,J Godwin,Richard Gray,C. Hicks,Spencer L. James,E MacKinnon,Paul McGale,T McHugh,Richard Peto,Carolyn W. Taylor,Yaochen Wang +15 more
TL;DR: It is found that variations in local treatment that substantially affect the risk of locoregional recurrence could also affect long-term breast cancer mortality, and that avoidance of a local recurrence in the conserved breast is recommended.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
TL;DR: Lymphedema is a common complication after treatment for breast cancer and factors associated with increased risk of lymphedEMA include extent of axillary surgery, axillary radiation, infection, and patient obesity.
Journal ArticleDOI
Clinical practice guidelines in oncology
William J. Gradishar,Benjamin O. Anderson,Ron Balassanian,Sarah L. Blair,Harold J. Burstein,Amy E. Cyr,Anthony D. Elias,William B. Farrar,Andres Forero,Sharon H. Giordano,Matthew P. Goetz,Lori J. Goldstein,Steven J. Isakoff,Janice A. Lyons,P. Kelly Marcom,Ingrid A. Mayer,Beryl McCormick,Meena S. Moran,Ruth O'Regan,Sameer A. Patel,Lori J. Pierce,Elizabeth C. Reed,Kilian E. Salerno,Lee S. Schwartzberg,Amy Sitapati,Karen L. Smith,Mary Lou Smith,Hatem Soliman,George Somlo,Melinda L. Telli,John H. Ward,Rashmi Kumar,Dorothy A. Shead +32 more
TL;DR: This manuscript focuses on the NCCN Guidelines Panel recommendations for the workup, primary treatment, risk reduction strategies, and surveillance specific to DCIS.
Journal ArticleDOI
Effect of radiotherapy after mastectomy and axillary surgery on 10-year recurrence and 20-year breast cancer mortality: meta-analysis of individual patient data for 8135 women in 22 randomised trials
Paul McGale,Carolyn W. Taylor,C Correa,D Cutter,F Duane,Marianne Ewertz,Richard Gray,Gurdeep S. Mannu,Richard Peto,Timothy J. Whelan,Yixin Wang,Zhe Wang,Sarah C. Darby +12 more
TL;DR: After mastectomy and axillary dissection, radiotherapy reduced both recurrence and breast cancer mortality in the women with one to three positive lymph nodes in these trials even when systemic therapy was given.
Journal ArticleDOI
Postoperative radiotherapy in high-risk postmenopausal breast- cancer patients given adjuvant tamoxifen: Danish Breast Cancer Cooperative Group DBCG 82c randomised trial
Marie Overgaard,Maj-Britt Jensen,Jens Overgaard,Per S. Hansen,Carsten Rose,Martin Andersson,Claus Kamby,Mogens Kjaer,Carl C. Gadeberg,Birgitte Bruun Rasmussen,Mogens Blichert-Toft,Henning T. Mouridsen +11 more
TL;DR: Postoperative radiotherapy decreased the risk of locoregional recurrence and was associated with improved survival in high-risk postmenopausal breast-cancer patients after mastectomy and limited axillary dissection, with 1 year of adjuvant tamoxifen treatment.
References
More filters
Journal ArticleDOI
Histological grading and prognosis in breast cancer; a study of 1409 cases of which 359 have been followed for 15 years.
H. J. G. Bloom,W. W. Richardson +1 more
TL;DR: This is a selection of photographs from around the world taken in the period of May 21 to 29, 1997, which were taken at the request of the then-president of the United States, George W. Bush.
Journal ArticleDOI
Adjuvant Cyclophosphamide, Methotrexate, and Fluorouracil in Node-Positive Breast Cancer — The Results of 20 Years of Follow-up
TL;DR: The long-term results of this trial of adjuvant combination chemotherapy confirm the preliminary observations of the effectiveness of the treatment in women with node-positive breast cancer.
Journal ArticleDOI
Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy.
Jack Cuzick,Helen J. Stewart,Lars Erik Rutqvist,Joan Houghton,Robert Edwards,C Redmond,Richard Peto,Michael Baum,Bernard Fisher,H. Host +9 more
TL;DR: The reduction of breast cancer deaths suggests that radiation therapy may have a value beyond the clearly established improvements obtainable for local control.
Journal ArticleDOI
Dose and Dose Intensity of Adjuvant Chemotherapy for Stage II, Node-Positive Breast Carcinoma
William C. Wood,Daniel R. Budman,Ann H. Korzun,M R Cooper,Jerry Younger,Ronald D. Hart,Anne Moore,J A Ellerton,Larry Norton,C R Ferree +9 more
TL;DR: The doses of chemotherapy used to treat breast cancers, especially early breast cancer, should not be reduced if the maximal benefit is to be achieved, according to either a dose-response effect or a threshold level of the dose or dose intensity.